GUD vs. ACB, OGI, CPH, CRDL, HLS, WEED, CRON, TLRY, EXE, and FRX
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Aurora Cannabis (ACB), Organigram (OGI), Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Canopy Growth (WEED), Cronos Group (CRON), Tilray Brands (TLRY), Extendicare (EXE), and Fennec Pharmaceuticals (FRX). These companies are all part of the "medical" sector.
Aurora Cannabis (TSE:ACB) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Aurora Cannabis currently has a consensus price target of C$2.26, suggesting a potential downside of 75.39%. Knight Therapeutics has a consensus price target of C$6.63, suggesting a potential upside of 12.24%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Aurora Cannabis.
Aurora Cannabis has a net margin of 151.71% compared to Aurora Cannabis' net margin of -5.13%. Aurora Cannabis' return on equity of -2.14% beat Knight Therapeutics' return on equity.
Aurora Cannabis received 418 more outperform votes than Knight Therapeutics when rated by MarketBeat users. However, 74.83% of users gave Knight Therapeutics an outperform vote while only 63.16% of users gave Aurora Cannabis an outperform vote.
Aurora Cannabis has higher earnings, but lower revenue than Knight Therapeutics. Knight Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Aurora Cannabis has a beta of 2.83, meaning that its share price is 183% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
In the previous week, Aurora Cannabis and Aurora Cannabis both had 4 articles in the media. Aurora Cannabis' average media sentiment score of 0.40 beat Knight Therapeutics' score of 0.22 indicating that Knight Therapeutics is being referred to more favorably in the news media.
7.0% of Aurora Cannabis shares are held by institutional investors. Comparatively, 13.7% of Knight Therapeutics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 46.4% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Knight Therapeutics beats Aurora Cannabis on 12 of the 17 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
